Literature DB >> 12393399

Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13).

Barbara Plaimauer1, Klaus Zimmermann, Dirk Völkel, Gerhard Antoine, Randolf Kerschbaumer, Pegah Jenab, Miha Furlan, Helen Gerritsen, Bernhard Lämmle, Hans Peter Schwarz, Friedrich Scheiflinger.   

Abstract

Deficient von Willebrand factor (VWF) degradation has been associated with thrombotic thrombocytopenic purpura (TTP). In hereditary TTP, the specific VWF-cleaving protease (VWF-cp) is absent or functionally defective, whereas in the nonfamilial, acquired form of TTP, an autoantibody inhibiting VWF-cp activity is found transiently in most patients. The gene encoding for VWF-cp has recently been identified as a member of the metalloprotease family and designated ADAMTS13, but the functional activity of the ADAMTS13 gene product has not been verified. To establish the functional activity of recombinant VWF-cp, we cloned the complete cDNA sequence in a eukaryotic expression vector and transiently expressed the encoded recombinant ADAMTS13 in HEK 293 cells. The expressed protein degraded VWF multimers and proteolytically cleaved VWF to the same fragments as those generated by plasma VWF-cp. Furthermore, recombinant ADAMTS13-mediated degradation of VWF multimers was entirely inhibited in the presence of plasma from a patient with acquired TTP. These data show that ADAMTS13 is responsible for the physiologic proteolytic degradation of VWF multimers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393399     DOI: 10.1182/blood-2002-05-1397

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity.

Authors:  Rens de Groot; David A Lane; James T B Crawley
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

2.  The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.

Authors:  Jihui Ai; Paula Smith; Shuwei Wang; Ping Zhang; X Long Zheng
Journal:  J Biol Chem       Date:  2005-06-23       Impact factor: 5.157

3.  Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood.

Authors:  Roberta Donadelli; Jennifer N Orje; Cristina Capoferri; Giuseppe Remuzzi; Zaverio M Ruggeri
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

4.  Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors:  Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

5.  ADAMTS13 and von Willebrand factor interactions.

Authors:  Catherine B Zander; Wenjing Cao; X Long Zheng
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

6.  Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W.

Authors:  C M Pruss; M Golder; A Bryant; C Hegadorn; S Haberichter; D Lillicrap
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

7.  Donor age affects liver regeneration during early period in the graft liver and late period in the remnant liver after living donor liver transplantation.

Authors:  Akihiro Tanemura; Shugo Mizuno; Hideo Wada; Tomomi Yamada; Tsutomu Nobori; Shuji Isaji
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.352

Review 8.  Thrombotic microangiopathies: multimers, metalloprotease, and beyond.

Authors:  Joel Moake
Journal:  Clin Transl Sci       Date:  2009-10       Impact factor: 4.689

Review 9.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 10.  ADAMTS13: more than a regulator of thrombosis.

Authors:  Yun Feng; Xueyin Li; Juan Xiao; Wei Li; Jing Liu; Xue Zeng; Xi Chen; Suhua Chen
Journal:  Int J Hematol       Date:  2016-10-01       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.